Search Within

Michael David Offin

  1. "Department of Pathology and Laboratory Medicine"
Formats
  1. Meeting Abstract (57)
  2. Journal Article (50)
  3. Editorial (2)
  4. Correspondence (1)
  5. Review (1)
Groups
  1. Department of Medicine (111)
  2. Department of Pathology and Laboratory Medicine (111)
  3. Solid Tumor Oncology Division (111)
  4. Thoracic Oncology (111)
  5. Weinberg Fellows (111)
  6. GSK Faculty (93)

More Groups

People
  1. Marc Ladanyi (57)
  2. Charles Rudin (56)
  3. Mark Kris (47)
  4. Alexander Drilon (45)
  5. Bob Li (43)
  6. Maria Arcila (42)

More People

Years
  1. 2025 (3)
  2. 2024 (15)
  3. 2023 (8)
  4. 2022 (14)
  5. 2021 (23)
  6. 2020 (9)

More Years

Publications
  1. Journal of Thoracic Oncology (23)
  2. Journal of Clinical Oncology (21)
  3. Clinical Cancer Research (12)
  4. Modern Pathology (8)
  5. JCO Precision Oncology (6)
  6. Laboratory Investigation (6)

More Publications

Publishers
  1. American Society of Clinical Oncology (27)
  2. Elsevier Inc. (27)
  3. American Association for Cancer Research (20)
  4. Nature Publishing Group (8)
  5. Nature Research (8)
  6. Oxford University Press (5)

More Publishers

Results (111)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Acquired ALK and RET gene fusions as mechanisms of resistance to osimertinib in EGFR-mutant lung cancers
    Journal Article

    Offin, M.; Somwar, R.; Rekhtman, N.; Benayed, R.; Chang, J. C.; Plodkowski, A.; Lui, A. J. W.; Eng, J.; Rosenblum, M.; Li, B. T.; more...
    JCO Precision Oncology (2018)

    Fulltext@MSK | Save
  • Evolution of a chemosensitive core-binding factor AML into an aggressive leukemia with eosinophilic differentiation
    Journal Article

    Xiao, W.; Yabe, M.; Offin, M.; Khattar, P.; Baik, J.; Daley, R. J.; Pappacena, J. J.; Roshal, M.; Zhang, Y.; Tallman, M. S.; more...
    Blood Advances (2018)

    Fulltext@MSK | Save
  • Oncogenic KRAS mediates resistance to MET targeted therapy in non-small cell lung cancer (NSCLC) with MET mutations that induce exon14 skipping
    Meeting Abstract

    Suzawa, K.; Offin, M. D.; Kurzatkowski, C.; Liu, D.; Vojnic, M.; Smith, R. S.; Mattar, M.; Khodos, I.; de Stanchina, E.; Sabari, J. K.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Noninvasive profiling of molecular dynamics in patients receiving HER2 targeted therapies by cell-free DNA analysis
    Meeting Abstract

    Gedvilaite, E.; Stewart, C.; Yang, J.; Reichel, J.; Stephens, D.; Offin, M. D.; Jing, X.; Meng, F.; You, D.; Berger, M. F.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Detecting HER2 alterations by next generation sequencing (NGS) in patients with advanced NSCLC from the United States and China
    Meeting Abstract

    Xu, C.; Zhang, Y.; Liu, D.; Shen, R.; Razavi, P.; Liu, S.; Sun, H.; Offin, M.; Drilon, A.; Rudin, C.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Molecular and imaging predictors of response to ado-trastuzumab emtansine in patients with HER2 mutant lung cancers: An exploratory phase 2 trial
    Meeting Abstract

    Li, B.; Offin, M.; Hembrough, T.; Cecchi, F.; Shen, R.; Olah, Z.; Panora, E.; Myers, M.; Brzostowski, E.; Buonocore, D.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • MET exon 14-altered lung cancers: Central nervous system (CNS) metastases and patterns of CNS progression on MET inhibition
    Meeting Abstract

    Offin, M.; Dienstag, J.; Wilkins, O.; Sabari, J.; Ni, A.; Feldman, D.; Van Voorthuysen, M.; Suzawa, K.; Yu, H.; Riely, G.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Utility of cfDNA testing for acquired resistance: The Memorial Sloan Kettering experience with plasma EGFR T790M clinical testing
    Meeting Abstract

    Offin, M.; Myers, M.; Josyula, S.; Shen, R.; Borsu, L.; Tsui, D.; Riely, G.; Rudin, C.; Yu, H.; Li, B.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Clinical and molecular characteristics of EGFR mutant lung cancers with concurrent TP53 and RB1 mutations
    Meeting Abstract

    Offin, M.; Tenet, M.; Shen, R.; Rekhtman, N.; Rizvi, H.; Hellmann, M.; Arcila, M.; Ladanyi, M.; Rudin, C.; Kris, M.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: Results from a phase II basket trial
    Journal Article

    Li, B. T.; Shen, R. L.; Buonocore, D.; Olah, Z. T.; Ni, A.; Ginsberg, M. S.; Ulaner, G. A.; Offin, M.; Feldman, D.; Hembrough, T.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save